By Authors

Publications - sorted by Authors

• Zrzavy T, Endmayr V, Bauer J, Macher S, Mossaheb N, Schwaiger C, Ricken G, Winklehner M, Glatter S, Breu M, Wimmer I, Kovacs G, Risser D, Klupp N, Simonitsch‐Klupp I, Roetzer T, Rommer P, Berger T, Gelpi E, Lassmann H, Graus F, Dalmau J, Höftberger R (2021) Neuropathological variability within a spectrum of NMDAR‐encephalitis. Ann Neurol, : 2021 Sep 25. doi: 10.1002/ana.26223. Online ahead of print.

• Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer B, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte H, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M (2020) On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study Transl Psychiat, 10 (2): 2
  | Weblink |

• Yuen H, Mackinnon A, Hartmann J, Amminger G, Markulev C, Lavoie S, Schäfer M, Polari A, Mossaheb N, Schlögelhofer M, Smesny S, Hickie I, Berger G, Chen E, de Haan L, Nieman D, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung A, McGorry P, Nelson B (2018) Dynamic prediction of transition to psychosis using joint modelling Schizophr Res, 202: 333-340
• Nelson B, Amminger G, Yuen H, Markulev C, Lavoie S, Schäfer M, Hartmann J, Mossaheb N, Schlögelhofer M, Smesny S, Hickie I, Berger G, Chen E, de Haan L, Nieman D, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung A, McGorry P (2018) NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course NPJ Schizophr, 4 (1): 11
• Mossaheb N, Schäfer M, Schlögelhofer M, Klier C, Smesny S, McGorry P, Berger M, Amminger G (2018) Predictors of longer-term outcome in the Vienna omega-3 high-risk study Schizophr Res, 193: 168-172
• Mossaheb N, Papageorgiou K, Schäfer M, Becker J, Schloegelhofer M, Amminger G (2018) Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids Early Interv Psychiatry, 12 (1): 30-36
• Mossaheb N, Kaufmann R, Schlögelhofer M, Aninilkumparambil T, Himmelbauer C, Gold A, Zehetmayer S, Hoffmann H, Traue H, Aschauer H (2018) The Impact of Sex Differences on Odor Identification and Facial Affect Recognition in Patients with Schizophrenia Spectrum Disorders Front Psychiatry, 9: 9
• McHugh M, McGorry P, Yuen H, Hickie I, Thompson A, de Haan L, Mossaheb N, Smesny S, Lin A, Markulev C, Schloegelhofer M, Wood S, Nieman D, Hartmann J, Nordentoft M, Schäfer M, Amminger G, Yung A, Nelson B (2018) The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo Schizophr Res, 195: 543-548
• Hinterbuchinger B, Litvan Z, Meyer E, Friedrich F, Kaltenboeck A, Gruber M, König D, Sueßenbacher S, Mossaheb N (2018) Psychotic-like experiences in esoterism: A twilight zone? Schizophr Res, 193: 240-243
• Hinterbuchinger B, Kaltenboeck A, Baumgartner J, Mossaheb N, Friedrich F (2018) Do patients with different psychiatric disorders show altered social decision-making? A systematic review of ultimatum game experiments in clinical populations Cogn. Neuropsychiatry, 23 (3): 117-141
• Mossaheb N, Schäfer M, Schlögelhofer M, Klier C, Smesny S, McGorry P, Berger M, Amminger G (2018) Predictors of longer-term outcome in the Vienna omega-3 high-risk study Schizophr Res, 193: 168-172
• Hinterbuchinger B, Litvan Z, Meyer E, Friedrich F, Kaltenboeck A, Gruber M, König D, Sueßenbacher S, Mossaheb N (2018) Psychotic-like experiences in esoterism: A twilight zone? Schizophr Res, 193: 240-243
• Mossaheb N, Kaufmann R, Schlögelhofer M, Aninilkumparambil T, Himmelbauer C, Gold A, Zehetmayer S, Hoffmann H, Traue H, Aschauer H (2018) The Impact of Sex Differences on Odor Identification and Facial Affect Recognition in Patients with Schizophrenia Spectrum Disorders Front Psychiatry, 9

• Bukenaite A, Stochl J, Mossaheb N, Schäfer M, Klier C, Becker J, Schloegelhofer M, Papageorgiou K, Montejo A, Russo D, Jones P, Perez J, Amminger G (2017) Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values Schizophr Res, 189: 69-74
• Hartmann J, McGorry P, Schmidt S, Amminger G, Yuen H, Markulev C, Berger G, Chen E, de Haan L, Hickie I, Lavoie S, McHugh M, Mossaheb N, Nieman D, Nordentoft M, Riecher-Rössler A, Schäfer M, Schlögelhofer M, Smesny S, Thompson A, Verma S, Yung A, Nelson B (2017) Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis Psychother Psychosom, 86 (5): 292-299
• Hinterbuchinger B, Mossaheb N (2017) Esoterik und Psychose//Esoterism and psychosis Journal für Neurologie, Neurochirurgie und Psychiatrie, 18 (3): 103-105
• Markulev C, McGorry P, Nelson B, Yuen H, Schaefer M, Yung A, Thompson A, Berger G, Mossaheb N, Schlögelhofer M, Smesny S, de Haan L, Riecher-Rössler A, Nordentoft M, Chen E, Verma S, Hickie I, Amminger G (2017) NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders Early Interv Psychiatry, 11 (5): 418-428
• McGorry P, Nelson B, Markulev C, Yuen H, Schäfer M, Mossaheb N, Schlögelhofer M, Smesny S, Hickie I, Berger G, Chen E, de Haan L, Nieman D, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung A, Amminger G (2017) Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders JAMA Psychiatry, 74 (1): 19-27
• McGorry P, Nelson B, Markulev C, Yuen H, Schäfer M, Mossaheb N, Schlögelhofer M, Smesny S, Hickie I, Berger G, Chen E, de Haan L, Nieman D, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung A, Amminger G (2017) Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders JAMA Psychiatry, 74 (1): 19
• Bukenaite A, Stochl J, Mossaheb N, Schäfer M, Klier C, Becker J, Schloegelhofer M, Papageorgiou K, Montejo A, Russo D, Jones P, Perez J, Amminger G (2017) Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values Schizophr Res, 189: 69-74
• Hartmann J, McGorry P, Schmidt S, Amminger G, Yuen H, Markulev C, Berger G, Chen E, de Haan L, Hickie I, Lavoie S, McHugh M, Mossaheb N, Nieman D, Nordentoft M, Riecher-Rössler A, Schäfer M, Schlögelhofer M, Smesny S, Thompson A, Verma S, Yung A, Nelson B (2017) Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis Psychother Psychosom, 86 (5): 292-299
• McHugh M, McGorry P, Yuen H, Hickie I, Thompson A, de Haan L, Mossaheb N, Smesny S, Lin A, Markulev C, Schloegelhofer M, Wood S, Nieman D, Hartmann J, Nordentoft M, Schäfer M, Amminger G, Yung A, Nelson B (2017) The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo Schizophr Res,

• Mossaheb N, Papageorgiou K, Schäfer M, Becker J, Schloegelhofer M, Amminger G (2015) Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids Early Interv Psychiatry, 12 (1): 30-36

• Mossaheb N, Aschauer H, Stoettner S, Schmoeger M, Pils N, Raab M, Willinger U (2014) Comprehension of metaphors in patients with schizophrenia-spectrum disorders Compr Psychiatry, 55 (4): 928-937
• Schlögelhofer M, Amminger G, Schaefer M, Fusar-Poli P, Smesny S, McGorry P, Berger G, Mossaheb N (2014) Polyunsaturated fatty acids in emerging psychosis: a safer alternative? Early Interv Psychiatry, 8 (3): 199-208

• Thompson A, Nelson B, Bruxner A, O'Connor K, Mossaheb N, Simmons M, Yung A (2013) Does specific psychopathology predict development of psychosis in ultra high-risk (UHR) patients? Aust N Z J Psychiatry, 47 (4): 380-390
• Amminger G, Allott K, Schlögelhofer M, Thompson A, Bechdolf A, Nelson B, Mossaheb N, Schäfer M (2013) Affect recognition and functioning in putatively prodromal individuals Schizophr Res, 147 (2-3): 404-405
• Velthorst E, Nelson B, O’Connor K, Mossaheb N, de Haan L, Bruxner A, Simmons M, Yung A, Thompson A (2013) History of trauma and the association with baseline symptoms in an Ultra-High Risk for psychosis cohort Psychiat Res, 210 (1): 75-81
• Mossaheb N, Schäfer M, Schlögelhofer M, Klier C, Cotton S, McGorry P, Amminger G (2013) Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: When do they begin to be effective? Schizophr Res, 148 (1-3): 163-167
• Mossaheb N, Schloegelhofer M, Kaufmann R, Werneck-Rohrer S, Zehetmayer S, Malik F, Khawar R, Chaudry H, Amminger G, Klier C, Aschauer H (2013) Duration of untreated psychosis in a high-income versus a low- and middle-income region Aust N Z J Psychiatry, 47 (12): 1176-1182

• Amminger G, Schafer M, Papageorgiou K, Klier C, Schlogelhofer M, Mossaheb N, Werneck-Rohrer S, Nelson B, McGorry P (2012) Emotion Recognition in Individuals at Clinical High-Risk for Schizophrenia Schizophr Bull, 38 (5): 1030-1039
• Amminger G, Schäfer M, Klier C, Schlögelhofer M, Mossaheb N, Thompson A, Bechdolf A, Allott K, McGorry P, Nelson B (2012) Facial and vocal affect perception in people at ultra-high risk of psychosis, first-episode schizophrenia and healthy controls Early Interv Psychiatry, 6 (4): 450-454
• Mossaheb N, Zehetmayer S, Jungwirth S, Weissgram S, Rainer M, Tragl K, Fischer P (2012) Are Specific Symptoms of Depression Predictive of Alzheimer’s Dementia? J Clin Psychiatry, 73 (07): 1009-1015
• Mossaheb N, Becker J, Schaefer M, Klier C, Schloegelhofer M, Papageorgiou K, Amminger G (2012) The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis Schizophr Res, 141 (2-3): 210-214

• Schosser A, Schloegelhofer M, Fuchs K, Stojanovic M, Mossaheb N, Kindler J, Cohen-Woods S, Hosang G, Farmer A, Craig I, McGuffin P, Aschauer H (2011) Bipolar disorder susceptibility region on chromosome 3q29 not confirmed in a case–control association study World J Biol Psychiatry, 12 (4): 309-315
• Kapusta N, Mossaheb N, Etzersdorfer E, Hlavin G, Thau K, Willeit M, Praschak-Rieder N, Sonneck G, Leithner-Dziubas K (2011) Lithium in drinking water and suicide mortality Br J Psychiatry, 198 (5): 346-350

• Schosser A, Fuchs K, Scharl T, Schloegelhofer M, Kindler J, Mossaheb N, Kaufmann R, Leisch F, Kasper S, Sieghart W, Aschauer H (2010) Interaction between serotonin 5-HT2A receptor gene and dopamine transporter (DAT1) gene polymorphisms influences personality trait of persistence in Austrian Caucasians World J Biol Psychiatry, 11 (2-2): 417-424
• Mossaheb N, Spindelegger C, Asenbaum S, Fischer P, Barnas C (2010) Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine World J Biol Psychiatry, 11 (2_2): 502-505

• Klein N, Wiesegger G, Attarbaschi T, Winkler D, Mossaheb N, Kasper S, Tauscher J (2004) A naturalistic observational study of escitalopram in the treatment of depression and anxiety disorder in adult outpatients Rom J Psychopharma, 4: 1-9